Navigation Links
Wyeth Announces Launch of Own Generic Version of PROTONIX
Date:1/29/2008

- Wyeth and Nycomed Continue Lawsuit to Enforce PROTONIX Patent -

MADISON, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and its business partner, Nycomed, today announced the U.S. launch of Wyeth's own generic version of PROTONIX(R) tablets, in response to the at-risk launch of generic pantoprazole tablets in the U.S. by Teva Pharmaceuticals USA, Inc. on December 21, 2007. Wyeth's own generic version of PROTONIX will be distributed by Prasco starting today.

"Compound patents, like that infringed by Teva, represent the foundation of pharmaceutical innovation, a critical underpinning in bringing important new medicines to patients," says Bernard Poussot, President and Chief Executive Officer for Wyeth. "We believe the PROTONIX compound patent is strong and we will vigorously pursue our litigation against Teva and other infringing generics. Going forward, we will continue to seek an injunction against any infringement of this patent, as well as monetary damages, including lost profits, from Teva."

Wyeth and Altana Pharma AG (recently acquired by Nycomed) sued Teva and Sun Pharmaceuticals for patent infringement based on Teva's and Sun's filing of Abbreviated New Drug Applications (ANDAs) seeking U.S. Food and Drug Administration (FDA) approval to market generic versions of PROTONIX before the patent expires on July 19, 2010. Under the Hatch-Waxman Act, the filing of the lawsuit stayed final FDA approval of Teva's ANDA until August 2, 2007, and Sun's ANDA until September 8, 2007. On September 6, 2007, The United States District Court for the District of New Jersey denied Wyeth's and Nycomed's motion for preliminary injunction. The Court did not rule on the validity of the patent, but rather concluded that, based on the limited record before it, Wyeth and Nycomed were not entitled to the extraordinary relief of a preliminary injunction. Trial is expected in the second half of 2008.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, we note that the impact of generic pantoprazole tablets on sales of PROTONIX cannot be predicted with certainty and will depend upon market and competitive conditions, the outcome of future proceedings in this litigation and other factors, many of which are beyond our control. We and our partner Nycomed may not be able to uphold the validity of the PROTONIX patent, recover our lost profits and other damages resulting from infringing sales and/or obtain a permanent injunction against further sales of generic pantoprazole. Other risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth Declares Common and Preferred Stock Dividends
2. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
3. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
4. Wyeth Sets Webcast and Conference Call for 2007 Fourth Quarter and Full Year Earnings
5. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth
6. Wyeth Receives Honors at the 2007 Scrip Awards
7. Wyeth Announces Executive Promotions
8. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
9. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
10. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
11. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... As New York’s fastest growing ophthalmic ... to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ... division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, Southampton, ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... recent partnership with an innovator in the wheelchair accessibility industry, BraunAbility . ... dealer salespeople to sell wheelchair accessible vehicles. With this new incentive plan, BraunAbility ...
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... ... manuscript in the Aesthetic Surgery Journal , the official journal of The ... conducted on lower eyelid retraction surgery. The procedure is designed to correct drooping, ...
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... In this ... in the United States for the asthma & allergy friendly mark. This certification program ... independently test and identify consumer products to be more suitable for the 60+ million ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Catherine ... http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ...      (Logo: ... European Neurological Review , ... Amey reports that despite standard care, temperatures ...
(Date:1/17/2017)... , Jan. 17, 2017  CSSi, the global ... the clinical research industry, will exhibit at the 8 ... Executives (SCOPE 2017), taking place from Tuesday, January 24 ... Miami in Miami, FL. ... proprietary technology platform, SmartStudy™ EMR, which provides a revolutionary ...
(Date:1/17/2017)... York , January 17, 2017 Transparency ... (Cinnamic Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market ... According to the report, the global benzaldehyde derivative market ... to reach US$ 2.14 Bn by 2024, expanding at a CAGR ... ...
Breaking Medicine Technology: